Renal Pelvic Denervation Pilot Trial
NCT07005050
This study is recruiting at 8 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose. The novelty of the RPDTM system relates to its placement via natural orifice into the renal pelvis (bilaterally) for delivery of radiofrequency energy to ablate the nerves that pass through the outer wall of the renal pelvis, a technique referred to as renal pelvic denervation (RPD).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Uncontrolled Hypertension
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 21 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Verve Medical, Inc
- Last updated on ClinicalTrials.gov
- October 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Alabama · 1
- University of Alabama at Birmingham · Birmingham, AL
Arizona · 1
- Panoramic Health / Southwest Kidney Institute, PLC · Surprise, AZ
California · 1
- Folio Clinical Research/Manchester Medical Group · Los Angeles, CA
Illinois · 1
- SIU School of Medicine · Springfield, IL
Iowa · 1
- University of Iowa Health Care · Iowa City, IA
Minnesota · 1
- University of Minnesota · Minneapolis, MN
Nevada · 1
- DaVita Clinical Research · Las Vegas, NV
Texas · 1
- Azura Vascular Care · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.